WCMNY
LYEL icon

Westchester Capital Management (New York)’s Lyell Immunopharma LYEL Stock Holding History

Westchester Capital Management (New York)’s Portfolio LYEL Stock Details LYEL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-25
Closed -$8K – 372
2021
Q2 		$8K Buy
+25
New +$8.2K ﹤0.01% 330

Other funds holding LYEL

MM
MWG Management Road Town, Tortola, British Virgin Islands $81.3M AUM 2.28% 1-Year Est. Return
A
Apoletto Road Town, Tortola, British Virgin Islands $260M AUM 31.4% 1-Year Est. Return
FCMI
Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
SM
SB Management Abu Dhabi, United Arab Emirates $516M AUM 40.71% 1-Year Est. Return
HH
HSG Holding Na, Hong Kong $1.62B AUM 5.91% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BOTOTLSJU
Board of Trustees of The Leland Stanford Junior University Redwood City, California $849M AUM 55.45% 1-Year Est. Return

Westchester Capital Management (New York)'s LYEL Position: Q3 2021 in Review

Westchester Capital Management (New York) sold out of Lyell Immunopharma (LYEL) in Q3 2021, closing a stake of 25 shares — an estimated $8K sold.

Westchester Capital Management (New York) first reported a position in LYEL in Q2 2021 and held it in 1 quarter. The position peaked at $8K in Q2 2021. 62 funds tracked by Wall St. Rank hold LYEL as of Q3 2021.

  • Westchester Capital Management (New York) reported no remaining Lyell Immunopharma position as of Q3 2021 after selling out during the quarter.
  • Westchester Capital Management (New York) sold 25 Lyell Immunopharma shares in Q3 2021, an estimated $8K.
  • Westchester Capital Management (New York) first reported a position in Lyell Immunopharma in Q2 2021 and held it in 1 quarter.
  • Westchester Capital Management (New York)'s Lyell Immunopharma position peaked at $8K in Q2 2021.
  • 62 funds tracked by Wall St. Rank held Lyell Immunopharma as of Q3 2021.

Based on Westchester Capital Management (New York)'s 13F filing for Q3 2021, filed 15 Nov 2021.